COVID-19 and Drug Repurposing

COVID-19 has expedited research on drug repurposing, a method that entails repurposing current pharmaceuticals. This strategy has proven invaluable throughout the pandemic since it makes use of well-known medications to promptly meet urgent requirements. Drugs that were initially designed for other illnesses, such as remdesivir and dexamethasone, have been proven to have therapeutic benefits for COVID-19 patients. Repurposing medications can lead to treatment more quickly than creating new ones from scratch. It also makes use of pre-existing safety data, which is important for responding to quickly changing health emergencies.

  • Mechanisms of Drug Repurposing
  • Clinical Trials and Evidence
  • Drug Candidates for COVID-19

  • Mechanisms of drug repurposing
  • Drug candidates for COVID-19

Related Conference of COVID-19 and Drug Repurposing

May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Paris, France
August 18-19, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
September 22-23, 2025

Pharma Biotech Expo

Toronto, Canada
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 20-21, 2025

21st Annual Congress on Pharmacology and Toxicology

Aix-en-Provence, France
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

13th International Conference on Clinical Trials

Amsterdam, Netherlands
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland

COVID-19 and Drug Repurposing Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in